<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854696</url>
  </required_header>
  <id_info>
    <org_study_id>38RC14.453</org_study_id>
    <nct_id>NCT02854696</nct_id>
  </id_info>
  <brief_title>Health Economic Analysis of Islet Cell Transplantation for the Stabilization of the Severe Forms of Type 1 Diabetes</brief_title>
  <acronym>STABILOT</acronym>
  <official_title>Health Economic Analysis of Islet Cell Transplantation for Patients With Severe Forms of Brittle Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal is to perform a cost-utility analysis to compare islet cell transplantation
      versus best medical treatment (defined as Sensor augmented pump therapy) for patients with
      brittle type1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal is to perform a cost-utility analysis to compare islet cell transplantation
      versus best medical treatment (defined as Sensor augmented insulin pump therapy) for patients
      with brittle type1 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental cost- utility ratio at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint will be the incremental cost-effectiveness ratio at one year for islet transplantation versus Best Medical Treatment of brittle type 1 diabetes.The effectiveness will be expressed as quality adjusted life years (QALYs) in a cost-utility analysis. QALYs are a composite measure of outcomes where utilities for health states (on 0-1 scale, where 0 corresponds to death and 1 to full health) act as qualitative weights to combine quantity and quality of life. The number of QALYs in each group will be assessed with the EuroQol 5 Dimensions questionnaire (EQ5D). The EQ-5D measures health status in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness ratio at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of the cost-effectiveness ratio at 1 year between islet cell transplantation versus best medical treatment (SAP therapy) for patients with brittle type 1 diabetes without impairment of vital prognosis. Two criteria of effectiveness will be used : the life years gained and the number of hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of individual medical benefit of quality of life</measure>
    <time_frame>6 months and 1year</time_frame>
    <description>Evaluate with DQOL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of individual medical benefit in terms of metabolic efficacy</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>measured from the following criteria: severe hypoglycemia, HbA1c, stimulated C-peptide, fasting glucose, insulin dose or oral diabetes, glycemic variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment and comparison of individual medical benefit in terms of complications of islet cell transplantation between the two groups</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>measured from in insulin independence, hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment and comparison of clinical benefit for patients with brittle type 1 diabetes with impairment of vital prognosis before and after islet cell transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>measured from DQOL, insulin independence, complications of islet cell transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment and comparison of costs for patients with brittle type 1 diabetes with impairment of vital prognosis before and after islet cell transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>measured from hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of total cost of islet cell transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of total cost of islet cell transplantation for patients with type 1 diabetes without impairment of vital prognosis, from pre-transplant period until 1 year after the last injection. Two perspectives will be used: French health care system and hospital.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Islet graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive islet graft Intervention : Procedure/Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who continue their optimal medical treatment (insulin pump therapy coupled with real time continuous glucose monitoring) Intervention : insulin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Islet graft</intervention_name>
    <description>Patients will be transplanted with pancreatic islet cells</description>
    <arm_group_label>Islet graft</arm_group_label>
    <other_name>islet cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>best medical care</intervention_name>
    <description>Patients will continue their insulin treatment</description>
    <arm_group_label>Best medical care</arm_group_label>
    <other_name>insulin treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Suffering from diabetes since more than 5 years

          -  Patient with brittle type 1 diabetes despite an optimized insulin treatment and
             educational training will be included. A patient will be considered as experiencing a
             brittle type 1 diabetes if at least two criteria are present among: persistence of
             severe hypoglycemia, occurrence of ketoacidosis events without obvious etiology,
             diagnosis of unaware hypoglycemic episodes &lt; 3 mmol/l based on CGM or self-monitoring
             blood glucose data, a mean blood glucose standard deviation&gt;50%, MAGE index (Mean
             amplitude of glucose excursions)&gt;60 mg/dl, LBGI index (low blood glucose index)&gt;5,
             Clarke score≥4 or HYPOSCORE&gt;800.

          -  Insulin needs &lt; 0,85 U/kg/day

          -  HbA1c &lt; 12% ;

          -  No residual insulin secretion (plasmatic basal and stimulated C-peptide &lt; 0.3 ng/ml)

          -  Social Security membership or benefit from Social Security

          -  Patients who signed the consent form

        Exclusion Criteria :

        Exclusion criteria related to islet infusion:

          -  Hemostatic disorders, pre-existing liver disease (PAL, Gamma-GT, ASAT-ALAT &gt;2N) or
             vesicular lithiasis.

        Exclusion criteria related to diabetic complications:

          -  Evolutive proliferative retinopathy, evolutive nephropathy (Glomerular filtration rate
             &lt;30 ml/min/1.73m2 and/or proteinuria &gt;0.5g/day), evolutive cardiopathy or obliterative
             arteriopathy with trophic cutaneous lesions.

        Exclusion criteria related to immunosuppressant use:

          -  Hemoglobin &lt; 110mg/dL in women and &lt; 120 mg/dL in men, leuconeutropenia, thrombopenia,
             systemic infection including chronic hepatitis B, C and VIH, neoplasia disease and
             hypertension&gt;160/100 mmHg.

          -  Corticoid treatment (except for patient that benefited from a kidney graft with
             maintenance steroid therapy)

          -  Presence of anti-HLA antibody directed against the donor

          -  Positive B or T cells crossmatch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Yves BENHAMOU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra DAVID TCHOUDA, MD, PhD</last_name>
    <phone>+33 476767186</phone>
    <email>SDavidTchouda@chu‐grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine MASSICOT</last_name>
    <phone>+33 476768860</phone>
    <email>SMassicot@chu‐grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie BOROT, MD, PhD</last_name>
      <phone>+33 3 81 66 82 29</phone>
      <email>sophie.borot@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie BOROT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>university hospital of Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor TAUVERON, MD, PhD</last_name>
      <phone>+33 4 73 75 15 29</phone>
      <email>itauveron@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Igor TAUVERON, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice ROCHE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine LABLANCHE, MD, PhD</last_name>
      <phone>+33 4 76 63 54 26</phone>
      <email>slablanche@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Myriam HADDOUCHE</last_name>
      <email>mhaddouche@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sandrine LABLANCHE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves BENHAMOU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel TETAZ, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine VANTYGHEM, MD, PhD</last_name>
      <phone>+33 3.20.44.45.35</phone>
      <email>Marie-Christine.VANTYGHEM@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Marie-Christine VANTYGHEM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François PATTOU, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noel NOEL, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristell LE MAPIHAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles THIVOLET, MDPHD</last_name>
      <phone>+33 4 78 86 14 87</phone>
      <email>charles.thivolet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Charles THIVOLET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel MORELON, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel BADET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny BURON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne WOJTUSCISZYN, MD, PhD</last_name>
      <phone>+33 4 67 33 83 86</phone>
      <email>a-wojtusciszyn@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Anne WOJTUSCISZYN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric RENARD, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie GIRERD, MD, PhD</last_name>
      <phone>+33 3.83.15.31.69</phone>
      <email>s.girerd@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Luc FRIMAT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie GIRERD, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno GUERCI, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>university hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy CHAILLOUS, MD, PhD</last_name>
      <phone>+33 2 53 48 27 01</phone>
      <email>lucy.chaillous@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Lucy CHAILLOUS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego CANTAROVICH, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre RIVELINE, MD, PhD</last_name>
      <phone>+33 1 49 95 83 79</phone>
      <email>jeanpierre.riveline@lrb.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nahima Geblaoui</last_name>
      <phone>+33 1 49 95 87 04</phone>
      <email>nahima.gueblaoui@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Pierre RIVELINE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre CATTAN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Noelle PERALDI, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine DURRBACH, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence KESSLER, MD, PhD</last_name>
      <phone>+33 3 88 11 62 67</phone>
      <email>laurence.kessler@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence KESSLER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, Pattou F, Berney T, Secchi A, Messinger S, Senior PA, Maffi P, Posselt A, Stock PG, Kaufman DB, Luo X, Kandeel F, Cagliero E, Turgeon NA, Witkowski P, Naji A, O'Connell PJ, Greenbaum C, Kudva YC, Brayman KL, Aull MJ, Larsen C, Kay TW, Fernandez LA, Vantyghem MC, Bellin M, Shapiro AM. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012 Jul;35(7):1436-45. doi: 10.2337/dc12-0063.</citation>
    <PMID>22723582</PMID>
  </reference>
  <reference>
    <citation>Beckwith J, Nyman JA, Flanagan B, Schrover R, Schuurman HJ. A health economic analysis of clinical islet transplantation. Clin Transplant. 2012 Jan-Feb;26(1):23-33. doi: 10.1111/j.1399-0012.2011.01411.x. Epub 2011 Feb 16.</citation>
    <PMID>21323736</PMID>
  </reference>
  <reference>
    <citation>Bellin MD, Kandaswamy R, Parkey J, Zhang HJ, Liu B, Ihm SH, Ansite JD, Witson J, Bansal-Pakala P, Balamurugan AN, Papas KK, Sutherland DE, Moran A, Hering BJ. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008 Nov;8(11):2463-70. doi: 10.1111/j.1600-6143.2008.02404.x. Epub 2008 Sep 19. Erratum in: Am J Transplant. 2010 May;10(5):1337. Papas, K [corrected to Papas, K K].</citation>
    <PMID>18808408</PMID>
  </reference>
  <reference>
    <citation>Badet L, Benhamou PY, Wojtusciszyn A, Baertschiger R, Milliat-Guittard L, Kessler L, Penfornis A, Thivolet C, Renard E, Bosco D, Morel P, Morelon E, Bayle F, Colin C, Berney T; GRAGIL Group. Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Transplantation. 2007 Jul 15;84(1):89-96.</citation>
    <PMID>17627243</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Islet cell Transplantation</keyword>
  <keyword>cost-effectiveness analysis</keyword>
  <keyword>Cost-utility analysis</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

